<DOC>
	<DOCNO>NCT00875147</DOCNO>
	<brief_summary>Hypothesis study : Neoadjuvant chemotherapy Bevacizumab impair postoperative outcome resection colorectal liver metastasis .</brief_summary>
	<brief_title>Impact Pre-operative Bevacizumab Complications After Resection Colorectal Liver Metastases</brief_title>
	<detailed_description>Bevacizumab humanize monoclonal antibody vascular endothelial growth factor ( VEGF ) increasingly add drug treatment colorectal cancer . Bev typically use combination chemotherapeutic agent oxaliplatin , irinotecan , leucovorin 5-fluorouracil ( 5-FU ) treatment patient CRLM . The objective study assess impact neoadjuvant bevacizumab clinical outcome hepatectomy colorectal liver metastasis ( CRLM ) . Patients , underwent liver resection due colorectal liver metastases neoadjuvant chemotherapy , operate 2005 2007 evaluate retrospectively . The patient distribute two group , either without bevacicumab . Outcome parameter mortality , complication , hospital stay ICU stay . To increase power study total number patient increase add patient center . Results adjust propensity develop complication .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients neoadjuvant chemotherapy prior liver resection Patients without neoadjuvant chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>bevacizumab</keyword>
</DOC>